As many states, patients, doctors and drug companies all desire to know more about CBD and its potential for various medical conditions, the U.S. Drug Enforcement Agency (DEA) has decided to go easy on those conducting CBD trials.
According to the CEO of one of the leading research companies developing synthetic CBD, Seth Yakatan, this is a great relief and a big step to help develop and prove CBD as an empirically efficacious compound. His company is developing synthetic CBD for conditions like Osteoporosis.
Since it is a schedule 1 controlled substance, strict restrictions have been heavily imposed to study the drug. But now that the DEA had eased up some of the restrictions, the time wasted waiting for the approval for more CBD can be used to hasten and make the trials more productive.